Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. We discovered a bone-targeting drug platform capable of precisely delivering small molecules, peptides, or large molecules directly to the site of broad bone fractures and disease designed to promote more rapid healing with fewer off-target safety concerns.
Advancing innovative precision therapeutics for debilitating and rare diseases
Our discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. Learn more about our bone-targeting drug platform and innovative precision therapeutics pipeline.
Quince in the news
Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone InjuryRead News Release